The VivoFect transfection reagent successfully developed by our team overcomes the limitation of commercially available transfection reagents, which cannot perform transfection in living muscle tissue. Currently, it has successfully achieved high-level expression of post-transfection gene products in small animals, and we hope to further apply this technology to clinical treatment in the future. In addition, experimental results show that our team's other product, VitroFect, exhibits transfection efficiency for suspension cells that is higher than all other products currently on the market. In recent years, there have been major breakthroughs in the application of cellular immunotherapy technology to cancer treatment. Its underlying principle is to effectively eliminate tumor cells in the body through the activation of the patient's own immune cells. However, the majority of immune cells in the human body are suspension cells. Therefore, the team hopes to utilize our self-developed VitroFect transfection reagent in the future through an ex-vivo approach to transfect immune cells with specific cancer cell surface antigens, thereby activating the body's immune response against cancer cells and achieving the capability to effectively eliminate cancer cells.
(The content above was translated by AI.)